Tag Archives: NASDAQ:CLVS

H.C. Wainwright Keeps Their Buy Rating on Clovis Oncology (CLVS)

H.C. Wainwright analyst Edward White reiterated a Buy rating on Clovis Oncology (CLVS – Research Report) today and set a price target of $237. The company’s shares closed on Friday at $23.48. According to TipRanks.com, White is a 5-star analyst

Clovis Oncology (CLVS) Gets a Hold Rating from J.P. Morgan

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Clovis Oncology (CLVS – Research Report) on April 2. The company’s shares closed on Friday at $25.67. According to TipRanks.com, Kasimov is a 3-star analyst with an average return of

A Director at Clovis Oncology (NASDAQ: CLVS) is Selling Shares

Today, a Director at Clovis Oncology (CLVS – Research Report), James C. Blair, sold shares of CLVS for $474K. See today’s analyst top recommended stocks >> Based on Clovis Oncology’s latest earnings report for the quarter ending December 31, the

J.P. Morgan Sticks to Its Hold Rating for Clovis Oncology (CLVS)

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Clovis Oncology (CLVS – Research Report) yesterday and set a price target of $27. The company’s shares closed yesterday at $26.05. Kasimov said: “Clovis’ 4Q report was as expected following

A Director at Clovis Oncology is Exercising Options

Today it was reported that a Director at Clovis Oncology (CLVS – Research Report), Thorlef Spickschen, exercised options to buy 32,758 CLVS shares at $0.87 a share, for a total transaction value of $28.74K. In addition to Thorlef Spickschen, 2

J.P. Morgan Thinks Clovis Oncology’s Stock is Going to Recover

In a report issued on October 19, Cory Kasimov from J.P. Morgan maintained a Buy rating on Clovis Oncology (NASDAQ: CLVS). The company’s shares closed on Friday at $26.36, close to its 52-week low of $26.13. According to TipRanks.com, Kasimov